Opus Genetics to Present at Upcoming Investor Conferences in March 2026 [Yahoo! Finance]
Opus Genetics, Inc. (IRD)
Company Research
Source: Yahoo! Finance
the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026 Time: 3:00 p.m. ET Location: Miami, FL Citizens Life Sciences Conference Date: Wednesday, March 11, 2026 Time: 2:50 p.m. ET Location: Miami, FL RBC Capital Markets Global Ophthalmology Conference Date: Wednesday, March 25, 2026 Time: 11:45 a.m. ET Location: Virtual Links to the conference webcasts may be accessed on Opus Genetics' website under the Investors section: Events About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.MarketBeat
- Opus Genetics (IRD) had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Opus Genetics (IRD) was given a new $9.00 price target by Craig Hallum. They now have a "buy" rating on the stock.MarketBeat
- Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
IRD
Sec Filings
- 3/13/26 - Form S-3
- 3/12/26 - Form PRE
- 3/12/26 - Form 10-K
- IRD's page on the SEC website